Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02784795
Title A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

cholangiocarcinoma

triple-receptor negative breast cancer

breast cancer

Advanced Solid Tumor

colon cancer

sarcoma

lymphoma

Therapies

Cisplatin + Gemcitabine + LY3039478

Carboplatin + Gemcitabine + LY3039478

LY3023414 + LY3039478

Abemaciclib + LY3039478

LY3039478 + Taladegib

LY3039478

LY3023414

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST